AstraZeneca’s AZD7442 Clinical Trial Meets Primary Endpoint October 12, 2021 Auto Bot News 0 AstraZeneca reports that its combination antibody therapy, AZD7442, reduced chances of severe COVID-19 or death by as much as 67%.
